IPHA
Innate Pharma

1,520
Mkt Cap
$164.98M
Volume
51,781.00
52W High
$3.51
52W Low
$1.41
PE Ratio
-3.00
IPHA Fundamentals
Price
$1.82
Prev Close
$1.79
Open
$1.83
50D MA
$1.98
Beta
0.40
Avg. Volume
22,782.78
EPS (Annual)
-$0.6602
P/B
27.32
Rev/Employee
$75,431.50
Loading...
Loading...
News
all
press releases
Innate Pharma to Present at Jefferies Global Healthcare Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced its business update and financial results for the first nine months of 2025. This quarter...
Business Wire·8d ago
News Placeholder
IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers
The company now intends to initiate the confirmatory trial in the first half of 2026.
Stocktwits·10d ago
News Placeholder
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
RegulatoryNews: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the...
Business Wire·11d ago
News Placeholder
Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday
Innate Pharma (NASDAQ:IPHA) will be releasing earnings before the market opens on Thursday, November 13. (View Earnings Report at...
MarketBeat·13d ago
News Placeholder
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks·14d ago
News Placeholder
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m...
Business Wire·16d ago
News Placeholder
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that it will host an analyst and investor event focused on lacutamab, an asset with path...
Business Wire·1mo ago
News Placeholder
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Szary Syndrome
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
Business Wire·9mo ago
News Placeholder
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the first patient was dosed in its Phase 1 study (NCT06781983), investigating the safety...
Business Wire·10mo ago

Latest IPHA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.